Morgan Stanley sees MRIdian ramp challenges, starts ViewRay at Equal Weight. As previously reported, Morgan Stanley analyst Jonathan Demchick started ViewRay with an Equal Weight rating and $7 price target, stating that the company’s MRIdian system has the potential to disrupt the $4B-$5B radiation therapy market, but he sees headwinds that will make it more challenging for ViewRay to reach and sustain profitability. These challenges include the fact that the system’s broader applicability across disease states is still up for debate, its price point versus conventional linacs is high, and Elekta’s MR linac presents competition, Demchick tells investors.Target $7.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.